Try our Advanced Search for more refined results

Teva-Ivax Merger Puts Spotlight On Authorized Generics

By Marius Meland (July 28, 2005, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd.'s $7.4 billion purchase of Ivax Corp. will once again propel the Israeli drug maker past Novartis as a leader in the $58-billion worldwide market for generic drugs. But the deal will force Teva to take a stand on the controversial practice of "authorized generics," analysts say....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!